Ignite Creation Date:
2024-05-06 @ 7:50 PM
Last Modification Date:
2024-10-26 @ 3:14 PM
Study NCT ID:
NCT06151197
Status:
RECRUITING
Last Update Posted:
2024-06-14
First Post:
2023-11-21
Brief Title:
Study to Assess EN3835 in the Treatment of Plantar Fibromatosis Also Known as Ledderhose Disease
Sponsor:
Endo Pharmaceuticals
Organization:
Endo Pharmaceuticals
Study Overview
Official Title:
A Phase 3 Double-blind Randomized Placebo-controlled Study to Assess the Efficacy Safety and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis PFI Also Known as Ledderhose Disease
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
STRIDE
Brief Summary:
This study will assess the efficacy safety and tolerability of EN3835 compared to placebo in the treatment of PFI also known as Ledderhose disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None